Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

/EIN News/ -- ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14^th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow.

Details of the presentations are as follows:
C1-Inhibitor Deficiency and Angioedema Workshop, Budapest, May 29-June 1, 2025.

• Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
  Presenter: Evangelia Pardali, Ph.D.
  Format: Oral Presentation, O-02
  Date, time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
• Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
  Presenter: Markus Magerl, M.D.
  Format: Poster Presentation, P-19
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
  Presenter: Zhi-Yi Zhang, Ph.D.
  Format: Poster Presentation, P-20
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Poster Presentation, P-17
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Oral Presentation, O-33
  Date, time: Saturday, May 31, 15:30-15:45 CEST (9:30-9:45 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: Marc A. Riedl, M.D., M.S.
  Format: Oral Presentation, O-34
  Date, time: Saturday, May 31, 15:45-16:00 CEST (9:45-10:00 a.m. ET)
• Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Poster Presentation, P-56
  Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
• Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Poster Presentation, P-42
  Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
• Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
  Presenter: Ramón Lleonart, M.D.
  Format: Poster Presentation, P-55
  Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
• Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Poster Presentation, P-30
  Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
  
  

2025 Eastern Allergy Conference, Palm Beach, Fl., May 29-June 1, 2025.

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, May 30, 9:45-11:00 a.m. ET
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, May 30, 9:45-11:00 a.m. ET
  
  

EAACI Congress 2025, Glasgow, June 13-16, 2025.

• Title: Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
  Presenter: Evangelia Pardali, Ph.D.
  Format: Flash Talk (e-Poster), Abstract #000949, FT03
  Date, time: Friday, June 13, 13:15-14:45 BST (8:15-9:45 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Thematic Poster Session (e-Poster and Poster Session) Abstract #000070
  Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
  Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000069
  Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
• Title: Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000331
  Date, time: Sunday, June 15, 12:45-13:45 BST (7:45-8:45 a.m. ET)
• Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Flash Talk (e-Poster), Abstract #000076, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: William Lumry, M.D.
  Format: Flash Talk (e-Poster), Abstract #000068, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
  Presenter: Markus Magerl, M.D.
  Format: Flash Talk (e-Poster), Abstract #000075, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone
  Presenter: Laurence Bouillet, M.D., Ph.D.
  Format: Oral Presentation, Abstract #000044, OAS18
  Date, time: Sunday, June 15, 15:45-17:15 BST (10:45 a.m.-12:15 p.m. ET)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Contact
                    Maggie Beller
                    Executive Director, Head of Corporate and Investor Communications
                    maggie.beller@pharvaris.com